Back to Search Start Over

The influence of collagen and hyaluronan matrices on the delivery and bioactivity of bone morphogenetic protein-2 and ectopic bone formation.

Authors :
Bhakta, Gajadhar
Lim, Zophia X.H.
Rai, Bina
Lin, Tingxuan
Hui, James H.
Prestwich, Glenn D.
van Wijnen, Andre J.
Nurcombe, Victor
Cool, Simon M.
Source :
Acta Biomaterialia; Nov2013, Vol. 9 Issue 11, p9098-9106, 9p
Publication Year :
2013

Abstract

Abstract: Bone morphogenetic protein-2 (BMP-2) is known to enhance fracture healing when delivered via a bovine collagen sponge. However, collagen rapidly releases BMP-2 with a high burst phase that is followed by a low sustained phase. As a result, supra-physiological doses of BMP-2 are often required to successfully treat bone defects. High BMP-2 dosing can introduce serious side effects that include edema, bone overgrowth, cyst-like bone formation and significant inflammation. As the release behavior of BMP-2 carriers significantly affects the efficacy of fracture healing, we sought to compare the influence of two BMP-2 delivery matrices with contrasting release profiles on BMP-2 bioactivity and ectopic bone formation. We compared a thiol-modified hyaluronan (Glycosilâ„¢) hydrogel that exhibits a low burst followed by a sustained release of BMP-2 to a collagen sponge for the delivery of three different doses of BMP-2, the bioactivities of released BMP-2 and ectopic bone formation. Analysis of bone formation by micro-computed tomography revealed that low burst followed by sustained release of BMP-2 from a hyaluronan hydrogel induced up to 456% more bone compared to a BMP-2 dose-matched collagen sponge that has a high burst and sustained release. This study demonstrates that BMP-2 released with a low burst followed by a sustained release of BMP-2 is more desirable for bone formation. This highlights the therapeutic potential of hydrogels, particularly hyaluronan-based, for the delivery of BMP-2 for the treatment of bone defects and may help abrogate the adverse clinical effects associated with high dose growth factor use. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
17427061
Volume :
9
Issue :
11
Database :
Supplemental Index
Journal :
Acta Biomaterialia
Publication Type :
Academic Journal
Accession number :
90524547
Full Text :
https://doi.org/10.1016/j.actbio.2013.07.008